These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 21512396)

  • 1. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
    Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
    Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fractal analysis of CT perfusion images for evaluation of antiangiogenic treatment and survival in hepatocellular carcinoma.
    Hayano K; Lee SH; Yoshida H; Zhu AX; Sahani DV
    Acad Radiol; 2014 May; 21(5):654-60. PubMed ID: 24703479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
    Lassau N; Koscielny S; Chami L; Chebil M; Benatsou B; Roche A; Ducreux M; Malka D; Boige V
    Radiology; 2011 Jan; 258(1):291-300. PubMed ID: 20980447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
    Frampas E; Lassau N; Zappa M; Vullierme MP; Koscielny S; Vilgrain V
    Eur J Radiol; 2013 May; 82(5):e205-11. PubMed ID: 23273822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
    Faivre S; Zappa M; Vilgrain V; Boucher E; Douillard JY; Lim HY; Kim JS; Im SA; Kang YK; Bouattour M; Dokmak S; Dreyer C; Sablin MP; Serrate C; Cheng AL; Lanzalone S; Lin X; Lechuga MJ; Raymond E
    Clin Cancer Res; 2011 Jul; 17(13):4504-12. PubMed ID: 21531821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression.
    Kambadakone A; Yoon SS; Kim TM; Karl DL; Duda DG; DeLaney TF; Sahani DV
    AJR Am J Roentgenol; 2015 Jan; 204(1):W11-8. PubMed ID: 25539263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
    Sugimoto K; Moriyasu F; Saito K; Rognin N; Kamiyama N; Furuichi Y; Imai Y
    Liver Int; 2013 Apr; 33(4):605-15. PubMed ID: 23305331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
    Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
    J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perfusion computed tomography in patients with hepatocellular carcinoma treated with thalidomide: initial experience.
    Petralia G; Fazio N; Bonello L; D'Andrea G; Radice D; Bellomi M
    J Comput Assist Tomogr; 2011; 35(2):195-201. PubMed ID: 21412089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Ippolito D; Querques G; Pecorelli A; Talei Franzesi C; Okolicsanyi S; Strazzabosco M; Sironi S
    J Comput Assist Tomogr; 2019; 43(2):206-213. PubMed ID: 30407241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma.
    Zhu AX; Holalkere NS; Muzikansky A; Horgan K; Sahani DV
    Oncologist; 2008 Feb; 13(2):120-5. PubMed ID: 18305056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
    Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
    Moschouris H; Malagari K; Gkoutzios P; Kalokairinou M; Stamatiou K; Chatzimichail K; Kornezos I; Karagiannis E; Kiltenis M; Papadaki MG
    Med Ultrason; 2012 Jun; 14(2):87-94. PubMed ID: 22675707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of whole-tumor dual-input perfusion CT in predicting the effect of multiarterial infusion chemotherapy on advanced non-small cell lung cancer.
    Li XS; Fan HX; Fang H; Huang H; Song YL; Zhou CW
    AJR Am J Roentgenol; 2014 Nov; 203(5):W497-505. PubMed ID: 25341164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
    Fournier LS; Oudard S; Thiam R; Trinquart L; Banu E; Medioni J; Balvay D; Chatellier G; Frija G; Cuenod CA
    Radiology; 2010 Aug; 256(2):511-8. PubMed ID: 20551183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
    Kim MJ; Choi JI; Lee JS; Park JW
    J Gastroenterol Hepatol; 2011 Jul; 26(7):1201-6. PubMed ID: 21371120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions.
    Ippolito D; Querques G; Okolicsanyi S; Talei Franzesi C; Pecorelli A; Lombardi S; Orsini E; Strazzabosco M; Sironi S
    Eur J Radiol; 2018 Sep; 106():62-68. PubMed ID: 30150052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermodality comparison between 3D perfusion CT and 18F-FDG PET/CT imaging for predicting early tumor response in patients with liver metastasis after chemotherapy: preliminary results of a prospective study.
    Kim DH; Kim SH; Im SA; Han SW; Goo JM; Willmann JK; Lee ES; Eo JS; Paeng JC; Han JK; Choi BI
    Eur J Radiol; 2012 Nov; 81(11):3542-50. PubMed ID: 22459347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
    Sahani DV; Jiang T; Hayano K; Duda DG; Catalano OA; Ancukiewicz M; Jain RK; Zhu AX
    J Hematol Oncol; 2013 Jul; 6():51. PubMed ID: 23842041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.